S&P 500   4,580.40 (+0.63%)
DOW   35,670.42 (+0.51%)
QQQ   381.89 (+0.50%)
AAPL   150.49 (+1.10%)
MSFT   323.71 (+0.17%)
FB   310.38 (-0.59%)
GOOGL   2,934.01 (+0.33%)
TSLA   1,066.26 (+2.74%)
AMZN   3,401.13 (+0.25%)
NVDA   246.36 (+0.76%)
BABA   167.68 (-0.92%)
NIO   39.40 (+0.23%)
CGC   12.79 (+0.08%)
GE   103.41 (-0.42%)
AMD   121.25 (-0.84%)
MU   69.44 (+1.76%)
T   25.31 (+1.00%)
F   17.00 (+9.61%)
ACB   6.82 (-0.29%)
DIS   169.40 (-0.09%)
PFE   43.30 (+0.77%)
BA   205.53 (-0.52%)
AMC   35.58 (+2.36%)
S&P 500   4,580.40 (+0.63%)
DOW   35,670.42 (+0.51%)
QQQ   381.89 (+0.50%)
AAPL   150.49 (+1.10%)
MSFT   323.71 (+0.17%)
FB   310.38 (-0.59%)
GOOGL   2,934.01 (+0.33%)
TSLA   1,066.26 (+2.74%)
AMZN   3,401.13 (+0.25%)
NVDA   246.36 (+0.76%)
BABA   167.68 (-0.92%)
NIO   39.40 (+0.23%)
CGC   12.79 (+0.08%)
GE   103.41 (-0.42%)
AMD   121.25 (-0.84%)
MU   69.44 (+1.76%)
T   25.31 (+1.00%)
F   17.00 (+9.61%)
ACB   6.82 (-0.29%)
DIS   169.40 (-0.09%)
PFE   43.30 (+0.77%)
BA   205.53 (-0.52%)
AMC   35.58 (+2.36%)
S&P 500   4,580.40 (+0.63%)
DOW   35,670.42 (+0.51%)
QQQ   381.89 (+0.50%)
AAPL   150.49 (+1.10%)
MSFT   323.71 (+0.17%)
FB   310.38 (-0.59%)
GOOGL   2,934.01 (+0.33%)
TSLA   1,066.26 (+2.74%)
AMZN   3,401.13 (+0.25%)
NVDA   246.36 (+0.76%)
BABA   167.68 (-0.92%)
NIO   39.40 (+0.23%)
CGC   12.79 (+0.08%)
GE   103.41 (-0.42%)
AMD   121.25 (-0.84%)
MU   69.44 (+1.76%)
T   25.31 (+1.00%)
F   17.00 (+9.61%)
ACB   6.82 (-0.29%)
DIS   169.40 (-0.09%)
PFE   43.30 (+0.77%)
BA   205.53 (-0.52%)
AMC   35.58 (+2.36%)
S&P 500   4,580.40 (+0.63%)
DOW   35,670.42 (+0.51%)
QQQ   381.89 (+0.50%)
AAPL   150.49 (+1.10%)
MSFT   323.71 (+0.17%)
FB   310.38 (-0.59%)
GOOGL   2,934.01 (+0.33%)
TSLA   1,066.26 (+2.74%)
AMZN   3,401.13 (+0.25%)
NVDA   246.36 (+0.76%)
BABA   167.68 (-0.92%)
NIO   39.40 (+0.23%)
CGC   12.79 (+0.08%)
GE   103.41 (-0.42%)
AMD   121.25 (-0.84%)
MU   69.44 (+1.76%)
T   25.31 (+1.00%)
F   17.00 (+9.61%)
ACB   6.82 (-0.29%)
DIS   169.40 (-0.09%)
PFE   43.30 (+0.77%)
BA   205.53 (-0.52%)
AMC   35.58 (+2.36%)
NASDAQ:VACC

Vaccitech News Headlines

$13.75
-0.25 (-1.79 %)
(As of 10/27/2021 04:00 PM ET)
Add
Compare
Today's Range
$13.74
$13.97
50-Day Range
$14.00
$16.50
52-Week Range
$12.25
$17.99
Volume
18,311 shs
Average Volume
15,523 shs
Market Capitalization
$472.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A

Media Mentions By Week



Vaccitech Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

VACC
News Sentiment

0.00

0.30

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

VACC Articles
This Week

2

1

VACC Articles
Average Week

Get Vaccitech News Delivered to You Automatically

Sign up to receive the latest news and ratings for VACC and its competitors with MarketBeat's FREE daily newsletter.

Vaccitech (NASDAQ:VACC) News Headlines Today

SourceHeadline
MarketBeat logoVaccitech (NASDAQ:VACC) Given "Buy" Rating at William Blair
americanbankingnews.com - October 23 at 11:24 AM
MarketBeat logoVaccitech plc's Lock-Up Period Set To End on October 27th (NASDAQ:VACC)
americanbankingnews.com - October 20 at 1:15 AM
MarketBeat logoVaccitech (NASDAQ:VACC) Sees Unusually-High Trading Volume
americanbankingnews.com - October 19 at 11:22 AM
finance.yahoo.com logoVaccitech Announces Data Presentations at AASLD’s Liver Meeting® 2021
finance.yahoo.com - October 18 at 8:31 AM
MarketBeat logoVaccitech plc (NASDAQ:VACC) Short Interest Update
americanbankingnews.com - October 18 at 7:20 AM
MarketBeat logoVaccitech (NASDAQ:VACC) Shares Gap Down to $15.33
americanbankingnews.com - October 14 at 11:16 AM
finance.yahoo.com logoVaccitech to Present an Update on Its Chronic HBV Infection Immunotherapeutic Program at The World Vaccine Congress Europe
finance.yahoo.com - October 13 at 10:24 AM
uk.finance.yahoo.com logoTaxpayer takes stake in Oxford vaccine co-creator
uk.finance.yahoo.com - September 14 at 4:47 AM
finance.yahoo.com logoVaccitech to Present at Upcoming September Investor conferences
finance.yahoo.com - September 9 at 9:38 AM
msn.com logoHow Oxford coronavirus vaccine technology could tackle diseases from cancer to HIV and the plague
msn.com - September 4 at 4:26 PM
finance.yahoo.com logoVaccitech Reports Second Quarter 2021 Financial Results and Recent Corporate Developments - Yahoo Finance
finance.yahoo.com - August 12 at 4:17 PM
finance.yahoo.com logoVaccitech Reports Second Quarter 2021 Financial Results and Recent Corporate Developments
finance.yahoo.com - August 12 at 4:17 PM
fool.com logoArbutus Biopharma (ABUS) Q2 2021 Earnings Call Transcript - The Motley Fool
fool.com - August 7 at 2:03 PM
seekingalpha.com logoArbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q2 2021 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 6 at 12:49 AM
finance.yahoo.com logoArbutus Reports Second Quarter 2021 Financial Results and Provides Corporate Update - Yahoo Finance
finance.yahoo.com - August 5 at 9:47 AM
nasdaq.com logoTesla, Inc.'s (NASDAQ:TSLA) Fundamentals are Improving but Valuation Remains a Risk - Nasdaq
nasdaq.com - July 31 at 11:12 PM
finance.yahoo.com logoVaccitech (NASDAQ:VACC) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
finance.yahoo.com - July 31 at 11:12 PM
nasdaq.com logoWe Think Vaccitech (NASDAQ:VACC) Can Afford To Drive Business Growth
nasdaq.com - July 31 at 12:44 AM
finance.yahoo.com logoVaccitech (NASDAQ:VACC) Is In A Good Position To Deliver On Growth Plans
finance.yahoo.com - July 30 at 7:43 PM
finance.yahoo.com logoVaccitech to Present at the William Blair Biotech Focus Conference 2021 - Yahoo Finance
finance.yahoo.com - July 8 at 5:21 PM
seekingalpha.com logoArbutus Bio collaborates with Vaccitech to AB-729 + VTP-300 in chronic hepatitis B virus - Seeking Alpha
seekingalpha.com - July 8 at 7:20 AM
finance.yahoo.com logoArbutus Biopharma, Vaccitech Team Up To Develop Combo Treatment For Hepatitis B - Yahoo Finance
finance.yahoo.com - July 7 at 10:20 AM
markets.businessinsider.com logoArbutus Biopharma, Vaccitech Team Up To Develop Combo Treatment For Hepatitis B
markets.businessinsider.com - July 6 at 1:15 PM
finance.yahoo.com logoArbutus Biopharma and Vaccitech Announce Clinical Trial Collaboration Agreement to Evaluate RNAi Therapeutic, AB-729, in Combination with Immunotherapeutic, VTP-300, in Subjects with Chronic Hepatitis B Virus Infection
finance.yahoo.com - July 6 at 8:15 AM
finance.yahoo.com logoVaccitech Reports First Quarter 2021 Financial Results and Recent Corporate Developments
finance.yahoo.com - June 14 at 7:37 PM
barrons.com logoVaccitech PLC ADR
barrons.com - June 3 at 5:59 PM
finance.yahoo.com logoVaccitech to Present at the Jefferies Virtual Healthcare Conference
finance.yahoo.com - June 1 at 8:19 AM
benzinga.com logoWilliam Blair Initiates Coverage On Vaccitech with Outperform Rating
benzinga.com - May 26 at 1:19 PM
benzinga.com logoJefferies Initiates Coverage On Vaccitech with Buy Rating, Announces Price Target of $28
benzinga.com - May 26 at 1:19 PM
finance.yahoo.com logoValneva Gains in Nasdaq Debut as Rival Vaccine Makers Fall
finance.yahoo.com - May 6 at 2:01 PM
finance.yahoo.com logoVaccitech Announces Closing of $110.5 Million Initial Public Offering
finance.yahoo.com - May 4 at 8:19 PM
nasdaq.com logoVaccitech plc American Depositary Shares (VACC)
nasdaq.com - May 3 at 8:32 AM
Get Vaccitech News Delivered to You Automatically

Sign up to receive the latest news and ratings for VACC and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 10/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.